What are the indications for prochlorperazine 5 mg?

Indications for Prochlorperazine 5 mg

Prochlorperazine 5 mg is indicated primarily for the treatment of nausea and vomiting, including chemotherapy-induced nausea/vomiting (CINV), radiation-induced emesis, migraine-associated nausea, and acute dizziness with associated nausea. 1

Primary Indications

Chemotherapy-Induced Nausea and Vomiting (CINV)

Prochlorperazine is specifically recommended for low to minimal emetogenic risk chemotherapy (Grade 1 or 2 emesis potential):

• Dosing: 10 mg orally pretreatment (optional), followed by 10 mg orally every 6 hours as needed 2
• Can be used with or without dexamethasone 20 mg orally 2
• May be administered intravenously at similar doses if oral route unavailable 2

For breakthrough CINV (when primary antiemetics fail):

• Dosing: 10 mg orally or IV every 4-6 hours, or 25 mg suppository rectally every 12 hours 3, 4
• Added as rescue therapy from a different drug class to the current regimen 3, 4

Migraine Headache

Prochlorperazine effectively relieves migraine headache pain and associated nausea:

• Dosing: 5-10 mg orally or IV 5, 6
• Functions both as adjunctive therapy for nausea and as a primary headache pain reliever 5
• Level A recommendation (must be offered) for IV prochlorperazine in emergency department migraine treatment 7

Radiation-Induced Emesis

For low emetogenic potential radiation therapy:

• Dosing: 10 mg orally or IV every 4-6 hours as needed 3
• Used as breakthrough treatment when prophylactic antiemetics fail 3

Acute Dizziness with Nausea

Prochlorperazine is effective for managing acute dizziness and associated symptoms:

• Dosing: 5 mg three times daily 8, 9
• Provides significant symptomatic relief from dizziness, nausea, and vomiting 9
• Mean effective dose approximately 14.9 mg/day for 7.2 days 9

Important Clinical Considerations

Formulation Details

• Available as 5 mg and 10 mg oral tablets 1
• The 5 mg dose is particularly appropriate for initial treatment of dizziness and as part of combination antiemetic regimens 8, 9

Common Pitfalls

• Monitor for extrapyramidal symptoms (EPS), though incidence is low at recommended doses (0.6% in real-world data) 9
• Do NOT use as first-line for high or moderate emetogenic chemotherapy—reserve for low-risk regimens or breakthrough treatment 2, 3
• When converting from liquid prochlorperazine mesilate to crushed tablets, doses should not be treated as equivalent due to drug loss during preparation 10
• Avoid promethazine IV except through central lines due to tissue damage risk 3, 4

Contraindications and Precautions

• Can impair driving performance, causing increased carelessness and slowing, though patients may not subjectively appreciate this impairment 8
• Less effective than metoclopramide/dexamethasone combinations for cisplatin-based chemotherapy 11
• More preferred by patients receiving carboplatin compared to cisplatin regimens 11

Adjunctive Therapy

• May be combined with lorazepam (0.5-2 mg) for anxiety management 2
• Can be used with H2 blockers or proton pump inhibitors for dyspepsia/reflux symptoms 4
• Diphenhydramine (25-50 mg) should be available to treat dystonic reactions if they occur 3